Drug Profile
PRCL 02
Alternative Names: PRCL02Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator PRCL Research Inc
- Class Antipsoriatics
- Mechanism of Action ORAI1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 25 Jul 2022 No development reported - Phase-II for Plaque psoriasis in Canada (PO)
- 25 Jul 2022 No development reported - Phase-II for Plaque psoriasis in Slovakia (PO)
- 25 Jul 2022 No development reported - Phase-II for Plaque psoriasis in Ukraine (PO)